The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.
Oxford Genetics and Sphere Fluidics to partner, alongside additional biopharma organizations, to develop automated systems for high-throughput gene editing in mammalian cell lines.
